Fiche publication
Date publication
novembre 2017
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GAUCHOTTE Guillaume
Tous les auteurs :
Liu J, Agopiantz M, Poupon J, Wu Z, Just PA, Borghese B, Ségal-Bendirdjian E, Gauchotte G, Gompel A, Forgez P
Lien Pubmed
Résumé
The high affinity receptor 1 (NTSR1) and its agonist, neurotensin (NTS), are correlated with tumor cell aggressiveness in most solid tumors. As chemoresistance and tumor aggressiveness are often related, we decided to study the role of the NTSR1 complex within platinum-based chemotherapy responses. In an ovarian model, we studied carboplatin because it is the main standard of care for ovarian cancer. Experimental tumors and studies were performed using SKOV3 and A2780 cells treated with carboplatin, with or without a very specific NTSR1 antagonist, SR48692. We measured the effects of these treatments on cell apoptosis and apoptosis-related proteins, platinum accumulation in the cell and nucleus, and the expression and localization of platinum transporters. NTS and NTSR1 labeling was measured in patients with ovarian cancer. SR48692 enhanced the response to carboplatin in ovarian cancer cells and experimental tumors. When SR48692 is combined with carboplatin, we noted a major improvement of platinum-induced DNA damage and cell death, as well as a decrease in tumor growth. The relationship of these results to clinical studies was made by the detection of NTS and NTSR1 in 72% and 74% of ovarian cancer, respectively. Furthermore, in a large series of high-grade ovarian cancer, NTSR1 mRNA was shown to correlate with higher stages and platinum resistance. This study strongly suggests that the addition of NTSR1 inhibitor in combination with platinum salt-based therapy will improve the response to the drug. .
Mots clés
Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, administration & dosage, Apoptosis, drug effects, Carboplatin, administration & dosage, Cell Line, Tumor, Cell Proliferation, drug effects, Drug Resistance, Neoplasm, drug effects, Female, Humans, Middle Aged, Ovarian Neoplasms, drug therapy, Pyrazoles, administration & dosage, Quinolines, administration & dosage, Receptors, Neurotensin, antagonists & inhibitors, Xenograft Model Antitumor Assays
Référence
Clin. Cancer Res.. 2017 Nov 1;23(21):6516-6528
